BRIEF published on 10/01/2024 at 00:56, 2 months 20 days ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
BRIEF published on 10/01/2024 at 00:45, 2 months 20 days ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
PRESS RELEASE published on 10/01/2024 at 00:40, 2 months 20 days ago Inside Information: News release on accounts, results Valerio Therapeutics reports its half-year 2024 financial results and updates on its activities, including the acquisition of Emglev Therapeutics and progress on the VIO-01 trial Acquisition Financial Results Valerio Therapeutics VIO-01 Trial Emglev Therapeutics
PRESS RELEASE published on 09/30/2024 at 22:40, 2 months 20 days ago Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
BRIEF published on 08/05/2024 at 19:23, 4 months 15 days ago Half-yearly review of the liquidity contract with Kepler Cheuvreux Liquidity Contract Transactions Kepler Cheuvreux AMF Valerio Therapeutics
PRESS RELEASE published on 08/05/2024 at 19:18, 4 months 15 days ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Valerio Therapeutics releases half-year liquidity contract statement revealing shares and trading volumes Liquidity Contract Shares AMF Decision Valerio Therapeutics Trading Volumes
BRIEF published on 06/05/2024 at 07:05, 6 months 16 days ago Minutes of the general meeting of Valerio Therapeutics Biotechnology Voting Results General Meeting Resolutions Valerio Therapeutics
PRESS RELEASE published on 06/05/2024 at 07:00, 6 months 16 days ago Inside Information / Other news releases Valerio Therapeutics reports successful Combined General Meeting with 48.1% quorum, adopting all resolutions. Consolidated vote results and meeting minutes to be available on the Company's website Euronext Growth Paris Biotechnology General Meeting Valerio Therapeutics DDR Drugs
BRIEF published on 05/22/2024 at 20:51, 6 months 29 days ago Valerio Therapeutics Advances VIO-01 Clinical Trial with Positive Results Drug Development Solid Tumors Clinical Trial Valerio Therapeutics VIO-01
PRESS RELEASE published on 05/22/2024 at 20:46, 6 months 29 days ago Inside Information / Other news releases Valerio Therapeutics completes dosing for first cohort of subjects in Phase 1/2 VIO-01 trial for solid tumors, showing encouraging tolerability. Phase 1b aims to determine recommended dose in selected solid tumors Solid Tumors Valerio Therapeutics VIO-01 Trial Phase 1/2 DNA Damage Response
Published on 12/21/2024 at 01:30, 17 hours 33 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 33 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 18 hours 58 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 19 hours 33 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 18 hours 12 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 18 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 23 hours 53 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:00, 1 day 1 hour ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 6 hours 46 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 5 hours ago Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago Share capital decrease by way of treasury shares cancellation
